Our responsibilities
At Johnson & Johnson Innovative Medicine, we believe in our responsibility to the communities in which we live and work. Our priority is developing safe, reliable and effective medicines. This work requires rigorous science and compassion —we have 40,000 people around the world who show up every day to innovate with purpose to lead where medicine is going.
Medicines can only help if people can get them.
-
Sustainability
With our resources, expertise and collaborations, we are taking action to test and champion sustainable access models to drive health forward for all in an increasingly complex world. -
Access and pricing
Medicines can only help if people can get them. Every step of our journey means nothing if our medicine does not reach its final destination -
Social impact
We are committed to grants and giving, and the principles of diversity, equity and inclusion in our workplace and beyond. -
Economic responsibility
Guided by our access and pricing principles, we continue to work to expand access to our medicines to help patients get the treatment they need. -
Communicable diseases
We’re focused on a targeted portfolio of programs and partnerships that build on our decades of work in communicable diseases.
Featured stories
-
Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
FNAIT is a rare disease that occurs when a pregnant person’s immune system attacks fetal platelets, resulting in the risk of internal bleeding, which can be life threatening to the fetus or newborn The Phase 3 FREESIA program is underway and nipocalimab is the only investigational therapy currently reported to be in clinical development for the treatment of FNAIT
